Efficacy of Linezolid in the management of pneumonic COVID-19 patients. Bioinformatics-based clinical study

Ragaey A Eid; Marwa O Elgendy; Ahmed M Sayed; Abdelrahman M Abdallah; Hayam MA Mostafa; Ahmed Mohammed M Elsisi; Ahmed M Hamed; Marwa Abdallah Shaker

doi:10.3855/jidc.19205

Efficacy of Linezolid in the management of pneumonic COVID-19 patients. Bioinformatics-based clinical study

Authors

Ragaey A Eid Department of Gastroenterology, Hepatology, and Infectious Diseases (Tropical Medicine Department), Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt https://orcid.org/0000-0002-3077-8265
Marwa O Elgendy Department of Clinical Pharmacy, Beni-Suef University Hospitals, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt
Ahmed M Sayed Department of Pharmacognosy, College of Pharmacy, Almaaqal University, 61014 Basrah, Iraq
Abdelrahman M Abdallah Department of Chest Diseases, Faculty of Medicine, Beni‐Suef University, Beni‐Suef, Egypt
Hayam MA Mostafa Beni-Suef University Hospitals, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt https://orcid.org/0009-0002-2491-4539
Ahmed Mohammed M Elsisi Biochemistry and Molecular Biology Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, Cairo, Egypt
Ahmed M Hamed Department of Internal Medicine, Faculty of Medicine, Beni‐Suef University, Beni‐Suef, Egypt
Marwa Abdallah Shaker Department of Gastroenterology, Hepatology, and Infectious Diseases (Tropical Medicine Department), Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt

DOI:

https://doi.org/10.3855/jidc.19205

Keywords:

Linazolid, pneumonia, SARS CoV-2, bioinformatics

Abstract

Introduction: At the beginning in July 2023, there has been a significant increase in daily hospital admissions attributed to the new variant of COVID-19. Aim of this study is to explore the clinical benefits and outcomes of using linezolid in the management of pneumonic COVID-19 patients.

Methodology: The study included 230 patients with SARS-CoV-2 infection confirmed by RT-PCR. Group 1: 118 patients were managed with Linazolid alongside steroids. Group 2: (control group) patients treated according to the Protocol for Egyptian COVID-19 management outlines and WHO guidelines (112 patients). Each patient group was categorized into 3 age groups: 20-40 years, 41-65 years, and over 65 years. Patients were carefully followed up until recovery or mortality. A docking analysis was carried out to investigate the potential of linezolid to act as an M^pro inhibitor.

Results: Group 1's average recovery time was 15.1 days in contrast to 18.7 days for Group 2 (control). There were no deaths reported. In silico investigations revealed that Linezolid was able to achieve a binding mode comparable to that of the co-crystalized inhibitor.

Conclusions: Linazolid is considered an effective antiviral weapon against SARS-COV-2. It could be used in the management plan of pneumonic individuals due to SARS-COV-2 infection. We recommend using it to combat the current wave caused by Omicron EG-5 Variant.

Downloads

Published

2024-03-31

How to Cite

Eid RA, Elgendy MO, Sayed AM, Abdallah AM, Mostafa HM, Mohammed M Elsisi A, Hamed AM, Shaker MA (2024) Efficacy of Linezolid in the management of pneumonic COVID-19 patients. Bioinformatics-based clinical study. J Infect Dev Ctries 18:326–331. doi: 10.3855/jidc.19205

Download Citation

Endnote/Zotero/Mendeley (RIS)

Issue

Vol. 18 No. 03: March 2024

Section

Coronavirus Pandemic

License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).